Dimaval (DMPS)

Quick links to important sections

Dimaval (DMPS)

Treatment option: Poisoning, Lead Poisoning

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dimaval (DMPS)

What is Dimaval (DMPS)?

Dimaval is a pharmaceutical preparation containing the active substance DMPS (2,3-dimercapto-1-propanesulfonic acid). It belongs to a class of compounds known as chelating agents, which are specifically designed to bind to certain substances within the body.

Chemical Nature and Function

The active component, DMPS, is a water-soluble derivative of dimercaprol. The molecule contains thiol groups—specifically sulfhydryl groups—which act as binding sites. These sites allow the compound to form stable complexes with various metal ions. Once a metal ion is bound to the DMPS molecule, it forms a complex known as a chelate.

Mechanism of Action

In the body, Dimaval works by circulating in the bloodstream and interstitial spaces. When it encounters compatible metal ions, the chemical attraction leads to the formation of these stable complexes. By converting free-floating or loosely bound metal ions into these chemically inert chelates, the substance facilitates their redistribution and subsequent elimination through the kidneys into the urine.

Therapeutic Application

Dimaval is utilized in clinical settings for the treatment of acute and chronic mobilizable intoxications involving heavy metals. Its high water solubility and distribution profile make it a primary option for addressing systemic presence of metals such as:

  • Mercury (in various chemical forms)
  • Lead
  • Copper
  • Antimony
  • Chromium
  • Cobalt

Because of its specific chemical structure, it is often selected when a rapid onset of chelation is required in an aqueous environment within the body tissues.

What side effects are possible with Dimaval (DMPS)?

Possible side effects and safety information

The official safety information for Dimaval (DMPS) categorizes potential adverse reactions according to the physiological system affected and the frequency with which they are reported in clinical use, based on regulatory standards.

Adverse effects are documented across several System-Organ Classes. These include reactions in the Immune System (such as fever and shivering, classified as uncommon), the Blood and Lymphatic System (leukopenia, categorized as rare or very rare), and the Gastrointestinal System (nausea and abdominal complaints). Certain cardio-vascular reactions, like a drop in blood pressure (hypotension), are also noted but classified as 'not known' in terms of frequency, often associated with rapid administration of the injection.

Serious Adverse Reactions and Safety Constraints

Specific serious adverse reactions explicitly noted in regulatory documents are rare but clinically significant. These include severe allergic skin responses such as Stevens-Johnson Syndrome and Erythema Exsudativum Multiforme, both classified as very rare. Additionally, the label notes a very rare risk of renal failure, which is attributed to the mobilization of mercury that can trigger clinical symptoms of poisoning.

Safety constraints define specific usage conditions. The medicine is formally contraindicated in individuals with known hypersensitivity to the active substance or excipients. Furthermore, the label requires that patients with pre-existing renal insufficiency receive concurrent dialysis if they are to be treated with Dimaval. Long-term use of the chelating agent is noted to potentially influence the balance of essential minerals, specifically zinc and copper.

Overdose and Emergency Response

The regulatory documentation for Dimaval (DMPS) defines the overdose profile by listing specific manifestations and outlining required emergency management procedures.

Documented Overdose Presentations

Overdose following the administration of the solution for injection is officially documented to present with systemic signs related to underlying cardiovascular effects. These clinical manifestations include blood pressure drop (hypotension), general weakness, and nausea. Localized overdose of the injectable solution can also lead to necroses at the injection site. The labeling notes a data limitation that overdose after oral administration has not been observed yet in clinical studies.

When to Seek Immediate Medical Help

Immediate medical attention is required for the management of the acute systemic symptoms noted above. Furthermore, patients must seek immediate medical attention if they experience severe allergic skin reactions, such as a severe rash or blistering, as this requires prompt physician intervention.

Official Management Procedures

The regulatory guidance on managing an overdose emphasizes procedural measures to remove the active substance. Haemodialysis (dialysis) is documented as an effective measure for removal. Supportive treatment includes the initiation of symptomatic therapy to manage adverse effects. General measures for poisoning, such as gastric lavage and plasma exchange, are also noted as applicable options.

Therapeutic Uses of Dimaval (DMPS)

Dimaval, which contains the active substance DMPS, is a chelating agent used across therapeutic domains where short-term symptomatic assistance is needed. Its primary use is in the clinical management of conditions associated with acute or disruptive episodes of heavy metal intoxication.

DMPS is a metal chelating agent used for managing poisoning with heavy metals such as mercury, lead, and arsenic. The medicine is applied in scenarios where additional management of discomfort is required due to the heightened systemic burden of heavy metals.

Its targeted action supports the body's general well-being during symptomatic phases. This may assist with maintaining a sense of stability when symptoms are more noticeable, and provides support that helps ease the overall symptom burden. It is commonly used to help with symptom clusters related to physical discomfort and systemic imbalance associated with acute or episodic changes. The use of DMPS provides support that helps ease the overall symptom burden: “It supports the patient during difficult episodes by easing distress.”


Quick Fact: Support for Symptom Clusters

Eligibility and Restrictions for Use

Who can and cannot use Dimaval (DMPS)?

Eligibility for Dimaval, an antidote used in heavy metal poisoning, is governed by specific rules set forth in regulatory documents, primarily based on the risk of adverse reactions and special patient conditions.

Contraindicated Populations:

The medicine is strictly contraindicated for any individual with a known hypersensitivity or allergy to the active substance (DMPS, or its salts) or any of its excipients.

Restricted and Special Consideration Populations:

Use is restricted or requires special medical consideration for several groups:

  • Renal Impairment: Patients experiencing renal insufficiency should only be treated with Dimaval if concurrent dialysis is being performed.
  • Pregnancy: While animal studies show no teratogenic effects, use during pregnancy is generally avoided as a precautionary measure. If deemed necessary for vital reasons, the patient’s mineral balance, especially zinc, must be closely monitored.
  • Lactation: Mothers who are contaminated with heavy metals are advised not to breast-feed in general.
  • Allergic Asthma: Special caution is recommended for patients with symptoms of allergic asthma.

Regulatory documentation primarily focuses on adult dosing, and the injection solution is specifically limited to patients who cannot take the oral form of the medicine.

What should I know about interactions with other medicines?

This section outlines established interactions with Dimaval (DMPS) based on regulatory documents.

Documented Interactions with Other Substances

The primary concern regarding interactions with oral Dimaval is the potential for chelation with other substances within the gastrointestinal tract, which can lead to a loss of the drug's effectiveness. For this reason, regulatory information explicitly lists two categories of substances to be avoided during simultaneous use.

Interacting Product Category Nature of Interaction Timing/Restriction
Mineral Preparations Chelation (binding) of DMPS to minerals in the intestine, reducing DMPS absorption and effectiveness. Do not take simultaneously.
Charcoal Chelation/Adsorption, reducing DMPS effectiveness. Avoid simultaneous administration.

Timing Requirements

To minimize the risk of chelation with essential minerals or components in food, oral Dimaval should be taken at least one hour prior to meals.

Population-Specific Monitoring

In the case of treatment of pregnant women with DMPS, the mineral balance, especially of zinc, should be carefully monitored. This is based on the understanding that chelation by a drug like DMPS could potentially influence the essential trace element balance, which is vital during pregnancy.

Mechanism of Action

Molecular Mechanism: Chemical Sequestration

Dimaval's (DMPS) action is a form of chelation, where the drug's molecule acts as a strong chemical ligand. The vicinal dithiol structure, featuring two adjacent sulfhydryl ( —SH) groups, enables it to form a stable, ring-like complex with specific toxic heavy metal ions (like inorganic mercury, arsenic, and lead). DMPS engages in ligand exchange, competitively displacing the metal ions from endogenous binding sites on essential proteins and enzymes. This process reduces the metal ion's chemical reactivity, influencing its interaction with endogenous sulfhydryl-containing biomolecules.


Systemic Mobilization and Renal Elimination Cascade

The mechanism of DMPS is structured for efficient clearance through the renal excretion pathway. The drug's molecular design includes a sulfonic acid group, which imparts high water-solubility to the newly formed DMPS-metal complex. This crucial chemical characteristic mobilizes the stable, non-toxic complex from soft tissues into the circulation, preventing it from re-depositing. The highly polar nature of the complex then facilitates its rapid and predictable filtration by the kidneys and expulsion via the urine. This sustained elimination via the kidneys reduces the total systemic concentration of the metal toxin.


Blood-Brain Barrier (BBB) Limitation

Due to the high polarity and water-solubility necessary for renal clearance, DMPS exhibits generally limited passive permeability across the blood-brain barrier. Consequently, its chelating action is primarily directed at metal deposits in peripheral tissues (kidneys, liver, blood) and is constrained regarding metals sequestered within the Central Nervous System (CNS).

Dosage and Administration Information

How to Use Dimaval (DMPS) – Official Administration Guidelines

Dimaval (DMPS) usage follows strict guidelines for administration, dosage, and frequency, which depend on whether the condition is acute or chronic. The medicine is supplied as a hard capsule for oral administration and a solution for injection for parenteral (intravenous or intramuscular) use.


Administration and Dosage Structure

The choice of administration route is generally based on the clinical situation. The injection is typically utilized for acute episodes or when a patient cannot take the medicine by mouth, while the oral form is generally reserved for managing chronic poisoning. Treatment duration is not fixed; instead, it is determined by laboratory findings, specifically the heavy metal excretion in the urine.

Instruction Application Principle (Official Labeling)
Route Selection Oral (Capsule) or Parenteral (IV/IM Injection).
Acute Dosing Begins with 250 mg every 3–4 hours on Day 1 (up to 2,000 mg max daily), with the frequency tapering over subsequent days.
Chronic Dosing Typical daily oral dose is 300 mg to 400 mg (3–4 capsules), divided into individual doses.

Key Procedural Constraints

The proper use of the medicine requires specific timing and preparation control. For oral use, the hard capsules must be taken at least one hour prior to meals with liquid; they must not be taken simultaneously with mineral preparations or activated charcoal. For intravenous injection, the solution must be administered slowly over three to five minutes and must not be mixed with other injection or infusion solutions. Furthermore, the official prescribing information restricts the use of the injectable solution in patients with impaired renal function unless dialysis is performed concurrently.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dimaval (DMPS)

The available research on Dimaval (DMPS) was studied for its use in certain cases of heavy metal exposure, primarily by monitoring changes in the amount of metal excreted from the body. Evidence highlights what is known — and what is still uncertain. Study results reflect the specific conditions under which they were conducted, and research provides context but not individual predictions.


Evidence for Use in Acute Inorganic Mercury Poisoning

Research exploring short-term changes in acute inorganic mercury poisoning has largely involved controlled animal experiments and observational case series in humans. What the studies reported is that they described patterns observed in the studies, with studies monitored increased measurements of mercury excretion in the urine after DMPS was given. Findings from animal models examined metal concentration in certain tissues. However, the evidence is limited; large-scale, randomized controlled trials ( RCTs) in humans are lacking, and follow-up durations were limited.


Evidence for Use in Chronic Arsenic Exposure (Arsenicosis)

Studies exploring chronic arsenic exposure included some RCTs and non-randomized comparative studies. Research examined outcomes related to physical discomfort by using clinical scoring systems for symptoms, as well as monitoring the concentration of arsenic excreted in the urine. Findings describe patterns observed in these studies, where clinical trials reported measurements of increased arsenic excretion. However, findings were mixed, and the available human trials generally have modest sample sizes. Long-term outcomes are not well characterized.


What is Still Uncertain About Dimaval (DMPS) Research

The evidence quality varies across studies, contributing to uncertainty across the indications studied. Key limitations include the fact that sample sizes were modest in many trials, and comparative evidence is lacking. Research is ongoing, but there is a clear need for more extensive, well-controlled studies with longer-term follow-up. Findings describe group patterns, and evidence highlights what is known — and what is still uncertain — about this compound.

Key Studies & References Chelating Agents in Metal Intoxication - LiverTox

Frequently Asked Questions (FAQ)

Common questions about Dimaval (DMPS) (FAQ)


Q: Is Dimaval the same as DMSA, and if not, what's the difference?

Dimaval (DMPS) and DMSA are both water-soluble drugs known as chelating agents, and they are chemical relatives of the older drug dimercaprol. While both are used to remove heavy metals like mercury, arsenic, and lead, they have slight differences in their chemical structure. These structural variations may lead to differences in their specific pharmacological profiles.


Q: How quickly should I expect to feel any effects from Dimaval?

According to pharmacokinetic data, the drug reaches its highest concentration in the blood approximately 3.7 hours after an oral dose. This pharmacokinetic data shows when the drug is available in the bloodstream. Perceived effects, if any, would follow this absorption phase.


Q: What are the most common side effects people report when taking Dimaval?

Official safety data indicates that the most frequently reported adverse effects are typically mild and reversible allergic skin reactions, such as rash or itching. These events are classified as uncommon, meaning they occur in less than 1% of patients. Nausea and abdominal complaints are also noted as rare side effects.


Q: Are there any common foods or supplements that interact badly with Dimaval?

Official prescribing information explicitly states that Dimaval must not be taken at the same time as mineral preparations or activated charcoal. The oral capsules should be taken at least one hour before any meal, as required by the product label, to help avoid chelation with food components.


Q: Is it true that Dimaval can lower mineral levels, like zinc or copper?

Yes, as a chelating agent that binds to metal ions, Dimaval can potentially influence the balance of essential minerals. Scientific evidence has specifically shown an increased excretion of zinc and copper in the urine during treatment. This effect is why monitoring the balance of essential minerals is often recommended during prolonged therapy.


Q: Why is Dimaval given by injection sometimes instead of pills?

The injection (intravenous or intramuscular) route is primarily reserved for treating acute, severe poisoning cases, or when a patient cannot take the medicine by mouth due to gastrointestinal issues. The parenteral administration is chosen in acute situations because it achieves higher drug availability more quickly than the oral route.


Q: How long does Dimaval stay in your system after you stop taking it?

The elimination half-life for the active compound in Dimaval is approximately 20 hours, which indicates the time required for the body to clear half of the dose. Most of the drug is ultimately eliminated through the urine.


Q: Can I take Dimaval if I'm already on blood pressure medication?

The official product label notes a potential risk of transient hypotension (a temporary drop in blood pressure), especially if the drug is administered too quickly via injection. To mitigate this potential cardiovascular effect, the intravenous solution must be administered slowly, as stated in the product guidelines.


Q: Are there any known long-term side effects of repeated Dimaval use?

Official safety constraints state that the long-term use of chelating agents like Dimaval may influence the body's balance of essential minerals. Specifically, the levels of zinc and copper should be monitored during prolonged or repeated use.


Q: What's the maximum amount of time someone typically uses Dimaval for?

The length of Dimaval treatment is not fixed and is determined on an individual basis by a healthcare provider. Decisions are based on the patient's condition and the results of laboratory tests, which track the amount of heavy metal being excreted in the urine.


Q: Does the form of Dimaval (pill vs. injection) make a big difference?

Yes, the form makes a significant difference in how it is used. The injection is preferred for acute or emergency cases because it acts faster. The oral pill is typically reserved for more stable patients or for ongoing chronic management.


Q: How is Dimaval absorbed by the body?

After taking the oral capsule, approximately 50% of the active ingredient is absorbed into the bloodstream. Once absorbed, it is transported throughout the body and is extensively bound to plasma proteins, primarily albumin.


Q: Is it normal to have a slight headache after a Dimaval infusion?

While the regulatory documents do not list headache as a common side effect, adverse events such as dizziness or weakness may occur, especially following a rapid infusion. These symptoms are generally not noted as being frequent.


Q: Does Dimaval actually remove heavy metals from the body?

Yes, the primary function of Dimaval as a chelating agent is to increase the body's ability to excrete heavy metals. It forms stable, non-toxic complexes with metal ions, which are then eliminated from the body, mainly through the urine. This process is intended to lower the overall body burden of the toxic metal.


Q: Can children safely use Dimaval, and under what conditions?

Official resources include Dimaval as a potential option for pediatric use, but it requires a physician’s prescription and careful medical supervision. This is due to the inherent risks of both the heavy metal poisoning and the complexity of the drug's use in children.


Q: Is Dimaval considered a proven treatment by mainstream medicine?

Dimaval has been available on official formularies in various countries for decades to treat certain heavy metal poisonings. However, regulatory reviews often note a general lack of large-scale, randomized, controlled clinical trials to clearly demonstrate its therapeutic efficacy across all conditions for which it is used.


Q: Has there been a lot of scientific research done on Dimaval?

Multiple studies, including animal research and small clinical trials, are cited in official reviews to support its mechanism and use. While research exists, regulators note limitations such as modest sample sizes and short follow-up periods, which contribute to the evidence quality.


Q: Is Dimaval available over the counter in some countries?

The drug is classified as a prescription-only medicine in the countries where it has formal regulatory approval. It is generally not available for purchase without a physician's prescription.


Q: What kind of medical professional typically oversees Dimaval treatment?

Treatment with Dimaval must be overseen by a physician. For cases of poisoning, consultation with a specialist, such as a medical toxicologist, is often strongly recommended when determining the appropriate course of therapy.


Q: Is Dimaval safe to use if I have a history of heart issues?

The regulatory documents do not list a history of general heart issues as a contraindication. However, rapid intravenous administration can cause a temporary drop in blood pressure (hypotension). The intravenous solution must be administered slowly to mitigate this potential cardiovascular effect.


Q: Can I take multivitamins while undergoing Dimaval treatment?

Official guidelines caution that trace elements and mineral preparations should not be given simultaneously with Dimaval, as the effectiveness of both can be reduced. Multivitamins often contain these minerals.


Q: Is Dimaval linked to any digestive issues like diarrhea or constipation?

Official side effect information lists gastrointestinal disorders, specifically including nausea and general abdominal complaints, as rare adverse effects. Diarrhea or constipation are not typically listed among the common side effects of the drug.


Q: Why do some people use Dimaval for mercury exposure?

People use Dimaval for mercury exposure because official research indicates that the drug effectively binds to mercury ions. This chelation process significantly increases the measured excretion of mercury in the urine, which helps to lower the overall body burden of the toxic metal.


Q: Is it normal to feel tired or nauseous after taking Dimaval?

Nausea is a listed, though rare, side effect of Dimaval. Weakness and dizziness may also occur, especially after rapid intravenous administration. General or common tiredness is not explicitly listed in the regulatory documents as a frequent adverse event.


Q: What are the signs that Dimaval treatment is working?

The most definitive sign is measured through laboratory tests that track the increased amount of metal being eliminated via the urine. This laboratory finding indicates the drug is successfully mobilizing and excreting the target heavy metal from the body.

How should Dimaval (DMPS) be stored and disposed of?

How to Store and Dispose of Dimaval (DMPS)?

Storage and disposal of Dimaval (DMPS) 100 mg Hard Capsules must adhere to the official requirements detailed in the product labeling to maintain stability and ensure safety.


Official Storage Requirements

Requirement Category Condition
Maximum Temperature Do not store above 25 C
Moisture Protection Keep the blister in the outer carton to protect from moisture
Child Safety Keep this medicine out of the sight and reach of children

Disposal Instructions

The regulatory labeling states there are no special requirements for the disposal of the unused product. Unused or expired Dimaval should be discarded in accordance with local regulations for pharmaceutical waste. Medicine must not be thrown away via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dimaval (DMPS) found in:

A-Z Index: